Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Should novobiocin be clinically re-evaluated?

R N Jones1

  • 1Clinical Microbiology Institute, Tualatin, Oregon.

Diagnostic Microbiology and Infectious Disease
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of a multiplex PCR to detect and identify Mycobacterium avium and M. intracellulare in blood culture fluids of AIDS patients.

Journal of clinical microbiology·1995
Same author

Asbestos: a risk too far?

Lancet (London, England)·1995
Same author

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.

Antimicrobial agents and chemotherapy·1995
Same author

Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.

The Pediatric infectious disease journal·1995
Same author

Evaluation of the Etest for determinations of antimicrobial spectrum and potency against anaerobes associated with bacterial vaginosis and peritonitis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1995
Same author

In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis.

Journal of chemotherapy (Florence, Italy)·1995
Same journal

Multiplex mismatch amplification mutation polymerase chain reaction assay for the rapid detection of antimicrobial-resistant determinants in Cutibacterium acnes.

Diagnostic microbiology and infectious disease·2026
Same journal

Tularemia-associated septic shock with pneumonia, lung abscesses, and pleural effusion leading to multiorgan failure: Is Francisella tularensis still a deadly pathogen in the antibiotic era? A case report.

Diagnostic microbiology and infectious disease·2026
Same journal

Impact of Xpert® MRSA/SA blood culture PCR test on antimicrobial utilization at a large teaching hospital.

Diagnostic microbiology and infectious disease·2026
Same journal

Disseminated Mucormycosis and monoclonal gammopathy in a young sarcoidosis patient following COVID-19: A rare case report.

Diagnostic microbiology and infectious disease·2026
Same journal

Human septic arthritis caused by Spiroplasma turonicum.

Diagnostic microbiology and infectious disease·2026
Same journal

Enhanced stability of RPA-CRISPR-Cas12a system for respiratory pathogen detection using Trehalose-Carboxymethyl Chitosan Lyoprotectant.

Diagnostic microbiology and infectious disease·2026
See all related articles

Novobiocin effectively inhibits most staphylococci, including oxacillin-resistant strains, and other bacteria. This suggests novobiocin could be a valuable option for treating resistant staphylococcal infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Oxacillin-resistant staphylococci pose a significant threat in healthcare settings.
  • Evaluating the antimicrobial spectrum of existing antibiotics is crucial for treatment strategies.

Purpose of the Study:

  • To assess the current antimicrobial activity of novobiocin against a wide range of bacterial isolates.
  • To determine the efficacy of novobiocin against oxacillin-resistant staphylococci and other relevant pathogens.

Main Methods:

  • Antimicrobial susceptibility testing was performed on 585 staphylococcal strains (393 oxacillin-resistant) and 779 other bacterial species.
  • Minimum Inhibitory Concentrations (MICs) were determined for novobiocin.

Main Results:

Related Experiment Videos

  • Novobiocin inhibited 98.5% of all staphylococcal isolates, with a MIC 90 of 0.25 µg/ml.
  • Significant activity was observed against other Gram-positive species (≤1 µg/ml).
  • Pathogenic Neisseria, Haemophilus influenzae, and Branhamella catarrhalis demonstrated high susceptibility (MIC 100 ≤1 µg/ml).

Conclusions:

  • Novobiocin exhibits broad-spectrum antimicrobial activity, particularly against staphylococci.
  • The findings support the potential utility of novobiocin in treating infections caused by oxacillin-resistant staphylococci and other susceptible bacteria.